Lynch Regenerative Medicine has received FDA authorization for two investigator-initiated clinical trials evaluating injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in facial aesthetics. The studies will examine its biological effects on facial skin and its potential use in treating under-eye hollowing.
Get the latest in Medical Aesthetics in our weekly ValuraNova Pulse. Sign up now.
The first trial, led by facial plastic surgeon Michael Somenek, MD, will enrol 12 participants to investigate changes in gene and protein expression associated with collagen, elastin and other extracellular matrix components following treatment. Skin biopsies will be collected at intervals ranging from seven days to eight weeks after injection, with completion expected in Q2 2027.
A second study, led by Sarah Allen, MD, will enrol 30 participants to assess the safety and potential efficacy of rhPDGF-BB injections for infraorbital hollowing. Researchers will evaluate changes in tear trough appearance, dark shadows, skin thickness, smoothness and brightness at 12 weeks, with completion anticipated in Q3 2027.
The trials follow a separate FDA-authorised Phase 2b study of injectable rhPDGF-BB for infraorbital hollowing. The new research will provide further insight into its potential regenerative applications in facial aesthetics, although the injectable treatment remains investigational and is not FDA-approved for these indications.
Read the full story here.






